S. 4472 explained · 119th Congress · Pending in Congress
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Cosponsors: 15 (8 D, 7 R) · per Congress.gov, 2026-10-14
Introduced: 2026-04-30
Latest action (2026-08-10): Held at the desk.
What S. 4472 does, in plain terms
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs. Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements. Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.
Official summary by the Congressional Research Service, via Congress.gov.
Constitution Index
“VFA Constitution grade”
Constitutionally sound
Graded 2026-10-11
SI-generated grade · five published checks · not individually reviewed by a person · methodology
The bill reauthorizes and revises federal programs supporting research and development for ALS and other neurodegenerative diseases. It operates within Congress's enumerated powers under the Spending Clause and the Commerce Clause, does not infringe on any constitutional rights, and appropriately delegates implementation to federal agencies. The programs are consistent with the Tenth Amendment as they involve voluntary federal spending and do not commandeer state governments. The bill's requirements for reporting and planning are procedural and do not implicate due process or takings concerns.
-
✓ Passes · Enumerated powers
Congress has authority under Article I, Section 8, Clause 1 (Spending Clause) to appropriate funds for the general welfare, which includes funding medical research. Additionally, the regulation of drugs and therapies falls under the Commerce Clause (Article I, Section 8, Clause 3) as it affects interstate commerce. The bill authorizes grants and establishes reporting requirements, all within these… -
✓ Passes · Bill of Rights
The bill does not restrict speech, religion, assembly, press, petition, the right to bear arms, or any other right protected by the Bill of Rights. It imposes no searches or seizures, no self-incrimination, no deprivation of life, liberty, or property without due process, and no cruel or unusual punishment. The provisions are limited to federal grant programs and agency planning, which do not impl… -
✓ Passes · Individual sovereignty
The bill does not restrict individual autonomy over person, property, speech, labor, or belief. It creates voluntary grant programs and imposes conditions on grantees, but these are not restrictions on individuals. The bill facilitates access to investigational drugs, which expands individual options rather than restricting them. No compelling constitutional justification is needed because no indi… -
✓ Passes · Decentralization
The bill addresses a national health crisis that requires coordinated federal research and regulatory efforts. An individual or family cannot independently fund and regulate drug development for ALS. Local communities and states lack the resources and jurisdiction to conduct nationwide clinical trials and FDA oversight. The federal government is the appropriate level to manage interstate drug deve… -
✓ Passes · Due process and takings
The bill does not deprive any person of life, liberty, or property without due process. It does not impose penalties or take property. The reporting and planning requirements are administrative and do not affect individual rights. The bill's provisions for grant renewal and safety reporting are procedural and do not implicate the Takings Clause (Fifth Amendment) because no private property is take…
Sources: Congress.gov: S 4472 summary
Report an error in this grade
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
Related on VFA
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
